BIRC5 and neoplasm: In pre-clinical studies, we demonstrate that survivin peptide (SVN53-67/M57) stimulated CTL responses against autologous and allogeneic tumor cells from patients with HLA-A*2901, HLA-A*3002 haplotypes [11].